FY2025 · ended Dec 31, 2025 · Revenue $559,000, -98.7% YoY · Filed Mar 5, 2026
Silence Therapeutics plc (SLN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $559,000 and a net loss of $88.6 million. Free cash flow was -$62.3 million. As of Jun 30, 2026 it held $72.1 million in cash and investments and $112,000 in total debt.
Revenue (TTM)
$615,000
Net income (TTM)
$-59.95M
Operating cash flow (TTM)
$-42.26M
Free cash flow (TTM)
$-42.27M
EPS (TTM)
$-0.42
Dividend per share
None
Shares outstanding
141.70M
+0.0% vs prior year
Net cash
$71.94M
as of Jun 30, 2026
Operating margin
-11106.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SLN (Nasdaq), SLNCF (OTC)
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1479615
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $559,000 | $43.3M |
| Operating income | -$91.1M | -$63.3M |
| Net income | -$88.6M | -$45.3M |
| Diluted EPS | -$0.63 | -$0.33 |
| Operating cash flow | -$62.3M | -$67.6M |
| Free cash flow | -$62.3M | -$67.9M |
| Total assets | $131.4M | $202.6M |
| Total liabilities | $69.1M | $68.6M |
| Stockholders' equity | $62.3M | $134.0M |
| Cash and investments | $85.1M | $147.3M |
| Total debt | $160,000 | $117,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 19, 2026 | Oct 18, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 12, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 16, 2026 | Jul 10, 2026 |
All 274 Silence Therapeutics plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.